Literature DB >> 27194720

Hippo signaling in the kidney: the good and the bad.

Jenny S Wong1, Kristin Meliambro1, Justina Ray1, Kirk N Campbell2.   

Abstract

The Hippo signaling pathway is an evolutionarily conserved kinase cascade, playing multiple roles in embryonic development that controls organ size, cell proliferation, and apoptosis. At the center of this network lie the Hippo kinase target and downstream pathway effector Yes-associated protein (YAP) and its paralog TAZ. In its phosphorylated form, cytoplasmic YAP is sequestered in an inactive state. When it is dephosphorylated, YAP, a potent oncogene, is activated and relocates to the nucleus to interact with a number of transcription factors and signaling regulators that promote cell growth, differentiation, and survival. The identification of YAP activation in human cancers has made it an attractive target for chemotherapeutic drug development. Little is known to date about the function of the Hippo pathway in the kidney, but that is rapidly changing. Recent studies have shed light on the role of Hippo-YAP signaling in glomerular and lower urinary tract embryonic development, maintenance of podocyte homeostasis, the integrity of the glomerular filtration barrier, regulation of renal tubular cyst growth, renal epithelial injury in diabetes, and renal fibrogenesis. This review summarizes the current knowledge of the Hippo-YAP signaling axis in the kidney under normal and disease conditions.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  Hippo; kidney; podocyte

Mesh:

Substances:

Year:  2016        PMID: 27194720      PMCID: PMC5005280          DOI: 10.1152/ajprenal.00500.2015

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  78 in total

1.  KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.

Authors:  S Moleirinho; N Chang; A H Sims; A M Tilston-Lünel; L Angus; A Steele; V Boswell; S C Barnett; C Ormandy; D Faratian; F J Gunn-Moore; P A Reynolds
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

2.  Sequential cell and tissue interactions governing organogenesis of the kidney.

Authors:  L Saxén; H Sariola; E Lehtonen
Journal:  Anat Embryol (Berl)       Date:  1986

3.  YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis.

Authors:  Stephen G Szeto; Masahiro Narimatsu; Mingliang Lu; Xiaolin He; Ahmad M Sidiqi; Monica F Tolosa; Lauren Chan; Krystale De Freitas; Janne Folke Bialik; Syamantak Majumder; Stellar Boo; Boris Hinz; Qinghong Dan; Andrew Advani; Rohan John; Jeffrey L Wrana; Andras Kapus; Darren A Yuen
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

4.  Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells.

Authors:  Wesley M Konsavage; Sydney L Kyler; Sherri A Rennoll; Ge Jin; Gregory S Yochum
Journal:  J Biol Chem       Date:  2012-02-15       Impact factor: 5.157

Review 5.  The epidermal growth factor receptor pathway: a model for targeted therapy.

Authors:  Maurizio Scaltriti; José Baselga
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

6.  YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis.

Authors:  Jian-Jia Cao; Xiu-Min Zhao; De-Lin Wang; Ke-Hong Chen; Xia Sheng; Wen-Bin Li; Mei-Cai Li; Wu-Jiang Liu; Jiang He
Journal:  Oncol Rep       Date:  2014-07-22       Impact factor: 3.906

7.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

8.  Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma.

Authors:  Zachary S Morris; Andrea I McClatchey
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-01       Impact factor: 11.205

9.  Yap and Taz are required for Ret-dependent urinary tract morphogenesis.

Authors:  Antoine Reginensi; Masato Hoshi; Sami Kamel Boualia; Maxime Bouchard; Sanjay Jain; Helen McNeill
Journal:  Development       Date:  2015-08-01       Impact factor: 6.868

10.  The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.

Authors:  Nailing Zhang; Haibo Bai; Karen K David; Jixin Dong; Yonggang Zheng; Jing Cai; Marco Giovannini; Pentao Liu; Robert A Anders; Duojia Pan
Journal:  Dev Cell       Date:  2010-07-20       Impact factor: 12.270

View more
  18 in total

1.  Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.

Authors:  Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Sonali Sinha; Christianna Howard; Darren P Wallace; Timothy A Fields; Andrew Leask; James P Calvet; Reena Rao
Journal:  J Am Soc Nephrol       Date:  2020-06-17       Impact factor: 10.121

Review 2.  Cross talk between the Crumbs complex and Hippo signaling in renal epithelial cells.

Authors:  U Michgehl; H Pavenstädt; B Vollenbröker
Journal:  Pflugers Arch       Date:  2017-06-13       Impact factor: 3.657

3.  The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.

Authors:  Ayumi Kaneda; Toshihiro Seike; Tomohiro Danjo; Takahiro Nakajima; Nobumasa Otsubo; Daisuke Yamaguchi; Yoshiro Tsuji; Kaori Hamaguchi; Mai Yasunaga; Yoichi Nishiya; Michihiko Suzuki; Jun-Ichi Saito; Rie Yatsunami; Satoshi Nakamura; Yoshitaka Sekido; Kiyotoshi Mori
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

4.  YAP mediates the interaction between the Hippo and PI3K/Akt pathways in mesangial cell proliferation in diabetic nephropathy.

Authors:  Xuan Qian; Linlin He; Meng Hao; Yuan Li; Xizhi Li; Yiqi Liu; Hong Jiang; Liu Xu; Chengcheng Li; Wenya Wu; Lei Du; Xiaoxing Yin; Qian Lu
Journal:  Acta Diabetol       Date:  2020-08-20       Impact factor: 4.280

Review 5.  The Hippo pathway: an emerging role in urologic cancers.

Authors:  Bekir Cinar; Esma Alp; Marwah Al-Mathkour; Ava Boston; Abdulrahman Dwead; Kezhan Khazaw; Alexis Gregory
Journal:  Am J Clin Exp Urol       Date:  2021-08-25

Review 6.  The Hippo Signaling Pathway in Development and Disease.

Authors:  Yonggang Zheng; Duojia Pan
Journal:  Dev Cell       Date:  2019-08-05       Impact factor: 12.270

7.  The signaling protein Wnt5a promotes TGFβ1-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap/Taz.

Authors:  Ye Feng; Yan Liang; Xingwen Zhu; Mingjie Wang; Yuan Gui; Qingmiao Lu; Mengru Gu; Xian Xue; Xiaoli Sun; Weichun He; Junwei Yang; Randy L Johnson; Chunsun Dai
Journal:  J Biol Chem       Date:  2018-10-17       Impact factor: 5.157

8.  Yap/Taz Deletion in Gli+ Cell-Derived Myofibroblasts Attenuates Fibrosis.

Authors:  Ming Liang; Michael Yu; Ruohan Xia; Ke Song; Jun Wang; Jinlong Luo; Guang Chen; Jizhong Cheng
Journal:  J Am Soc Nephrol       Date:  2017-08-02       Impact factor: 10.121

9.  Characterization of Coding/Noncoding Variants for SHROOM3 in Patients with CKD.

Authors:  Jeremy W Prokop; Nan Cher Yeo; Christian Ottmann; Surya B Chhetri; Kacie L Florus; Emily J Ross; Nadiya Sosonkina; Brian A Link; Barry I Freedman; Candice J Coppola; Chris McDermott-Roe; Seppe Leysen; Lech-Gustav Milroy; Femke A Meijer; Aron M Geurts; Frank J Rauscher; Ryne Ramaker; Michael J Flister; Howard J Jacob; Eric M Mendenhall; Jozef Lazar
Journal:  J Am Soc Nephrol       Date:  2018-02-23       Impact factor: 10.121

Review 10.  Analysis of the role of the Hippo pathway in cancer.

Authors:  Yanyan Han
Journal:  J Transl Med       Date:  2019-04-08       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.